Government bans manufacture of Meningitis drug

The government has banned Liposomal Amphotericin B, an injection-based drug used to treat potentially life threatening fungal infections, including meningitis. Chemical salt, amphotericin B, features among the National List of Essential Medicines.
The government has banned Liposomal Amphotericin B, an injection-based drug used to treat potentially life threatening fungal infections, including meningitis.(Shutterstock)
The government has banned Liposomal Amphotericin B, an injection-based drug used to treat potentially life threatening fungal infections, including meningitis.(Shutterstock)
Updated on Apr 01, 2016 03:39 PM IST
Copy Link
Hindustan Times | By, New Delhi

The government has banned Liposomal Amphotericin B, an injection-based drug used to treat potentially life threatening fungal infections, including meningitis. Chemical salt, amphotericin B, features among the National List of Essential Medicines.

Ambisome, Fungizone, Envocin, Lambin and Amphoject are some of the injection-based drugs made from amphotericin B.

“The increasing complaints of potential side-effects on kidney and liver has led us to write letters to state drug regulators. We have asked them to suspend licences for manufacture of Liposomal Amphotericin B. The regulators have informed companies,” GN Singh, Drug Controller General of India (DCGI), told HT.

About seven companies, including Abbott, Sun Pharma, Cipla, Panacea Biotech and Bharat Serums, market or manufacture the same drug under different brand names.

The cost of a single injection is varies from `1,800 to `8,000.

The ban is not the part of previously announced ban on fixed-dose combination (FDC) drugs.

“The decision is taken for patient’s safety and there are many safe alternatives available in the market,” Singh added.

Most of the companies, including Abbott and Panacea Biotech, procure this product under their trade names from outsourced manufacturers.

“Our company does not manufacturer this product and neither carries any licence in this respect. We have sent the above reply to the DCGI,” a spokesperson of Panacea Biotech said.

Cipla, Sun Pharma and Abbott did not respond to HT’s requests for comments.

SHARE THIS ARTICLE ON
  • ABOUT THE AUTHOR

    Himani Chandna is a Delhi-based journalist covering the business of healthcare, pharmaceuticals, human resources and brands

Close Story
SHARE
Story Saved
×
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Saturday, May 28, 2022